The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

High Energy Chemistry / Hazardous Chemistry-based API Manufacturing Services Market: Focus on High Temperature, Low Temperature / Cryogenic, High Pressure and Low Pressure Chemistries, 2020-2030

  • Lowest Price Guaranteed From USD 4,899

  • Published
    June 2020

  • Pages
    247

  • View Count
    712

Example Insights

High-Energy-Chemistry-Hazardous-Chemistry-based-API-Manufacturing-Services-Market-Context 	High-Energy-Chemistry-Hazardous-Chemistry-based-API-Manufacturing-Services-Market-Service-providers High-Energy-Chemistry-Hazardous-Chemistry-based-API-Manufacturing-Services-Market-landscape
High-Energy-Chemistry-Hazardous-Chemistry-based-API-Manufacturing-Services-Market-Distribution-by-temperature High-Energy-Chemistry-Hazardous-Chemistry-based-API-Manufacturing-Services-Market-Stakeholders 	High-Energy-Chemistry-Hazardous-Chemistry-based-API-Manufacturing-Services-Market-Portfolio-of-reactions
High-Energy-Chemistry-Hazardous-Chemistry-based-API-Manufacturing-Services-Market-Case-in-point High-Energy-Chemistry-Hazardous-Chemistry-based-API-Manufacturing-Services-Market-forecast  

 

Overview

In pharmaceutical manufacturing, the use of certain hazardous chemical reactions has been shown to enable developers to optimize existing production processes, as well as improve yields. In other words, certain chemical reactions, which are generally regarded as harmful, offer a more direct route to the end product, requiring fewer raw materials and involving a limited number of side reactions. As a result, the number of process steps are essentially reduced, when compared to using conventional synthesis chemistries. Prominent examples of hazardous chemical reactions include nitrations, oxidations, hydrogenations, alkylations, and reactions involving unstable or highly active compounds (such as azides, nitrate esters, peroxides, diazo compounds and highly potent substances). Generally, such reactions are carried out under specialized temperature and pressure conditions. However, they are usually not considered during the early drug development stages, owing to the associated risks. From a large-scale manufacturing perspective, the use of such techniques has been proven to offer substantial time and cost-related benefits. In this context, it is also worth mentioning that using hazardous synthesis chemistries it is possible to design new chemical structures, which have interesting bio-active properties, and offer the means to improve overall product quality.

Given the inherent risks associated with hazardous chemistry-based manufacturing processes, innovator companies (especially in the fine chemicals and pharmaceutical industries) prefer to outsource such processes to contract service providers. Presently, there are a number of contract chemicals manufacturers that claim to have the necessary capabilities and infrastructure to support the synthesis of APIs under hazardous conditions. It is worth highlighting that such reactions are best contained within continuous flow processes. However, owning to various reasons (such as reaction specific complexities, fluctuating volumes and certain application specific requirements) the fine chemicals and pharmaceutical industries tend to rely on the traditional batch process. However, there is an evident shift in operating preferences to continuous systems, which is anticipated to bring about revolutionary changes in the long term. Considering the growing global population and the rising demand for new and effective drugs, faster and more efficient pharmaceutical manufacturing processes have become a necessity. In fact, if a drug against COVID-19 is successfully developed, it is imperative to develop high efficiency processes to ensure the production of sufficient volumes of the therapeutic to treat the global population. We are led to believe that the use of high energy chemistry and hazardous chemistries have much to offer in the aforementioned context. As a consequence, the contract services market catering to this segment of the pharmaceutical industry is anticipated to witness substantial growth in the coming years.

Scope of the Report

The ‘High Energy Chemistry / Hazardous Chemistry-based API Manufacturing Services Market: Focus on High Temperature, Low Temperature / Cryogenic, High Pressure and Low Pressure Chemistries, 2020-2030’ report features an extensive study on the current landscape and the likely future potential of the companies offering services for API manufacturing based on high energy chemistry (HEC) / hazardous chemistry. The study features an in-depth analysis, highlighting the capabilities of a diverse set of industry stakeholders. Amongst other elements, the report features:

  • A detailed review of the overall landscape of companies offering contract and custom services for HEC / hazardous chemistry-based API manufacturing, along with information on type of manufacturer (contract and custom manufacturer), year of establishment, company size, location of headquarters, number and location of manufacturing facilities, general service portfolio (type of product (APIs, intermediates, and drug products), HPAPI manufacturing capability and availability of continuous flow technology), HEC specific service portfolio (type of  conditions handled such as high temperature, low temperature, high pressure, low pressure for API manufacturing processes). 
  • A detailed list of over 125 manufacturing facilities equipped to handle API manufacturing processes / reactions under high temperature, low temperature, high pressure and low pressure conditions. The chapter features geographical map representations highlighting the location of these manufacturing facilities, along with logo landscape of manufacturers. The chapter also presents a detailed regional capability assessment framework which compares the capabilities of companies (based on manufacturing facilities) across different regions. It further include information on type of reaction conditions handled (high temperature, low temperature, high pressure, low pressure) and operating range. 
  • A competitiveness 3-D bubble analysis of HEC / hazardous chemistry-based contract and custom manufacturers, taking into consideration supplier strength (based year of establishment), service strength (general service portfolio (API, intermediate and FDF, availability of continuous flow technology), HEC / hazardous chemistry-based service portfolio (capability to handle API manufacturing processes under conditions, including high temperature, low temperature, high pressure, low pressure and other hazardous reaction capabilities), and number of HEC-specific manufacturing facilities of companies. 
  • Elaborate profiles of the key players that offer a diverse range of capabilities for API manufacturing based on HEC / hazardous chemistry. Each profile includes a brief overview of the company, financial information (if available), details related to manufacturing facilities (pharmaceutical manufacturing facilities and HEC / hazardous chemistry specific facilities), information related to its HEC / hazardous chemistry based API manufacturing service portfolio (high temperature and low temperature reaction conditions handled, portfolio of hazardous reactions), recent developments and an informed future outlook.
  • A case study providing insights on the general reaction portfolio related to small molecule synthesis processes. We have presented this information for HEC / hazardous chemistry-based companies, along with information on the availability of continuous flow technology and capabilities to handle varied reaction conditions, such as high temperature, low temperature, high pressure, and low pressure controls. 
  • A detailed case study presenting a list of contract research organizations (CROs) and custom synthesis service providers which claim to have the required capabilities to provide a wide range of services, ranging from process development (including preliminary R&D), scale-up and small scale synthesis, for APIs based on HEC / hazardous chemistry.
  • A discussion on affiliated trends, key drivers and challenges which are likely to impact the industry’s evolution, under an elaborate SWOT framework. It also includes a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall industry.  

One of the key objectives of this report was to estimate the existing market size and the future growth potential within the HEC / hazardous chemistry-based API manufacturing services market. Based on multiple parameters, such as growth of the overall pharmaceutical drugs market, cost of goods sold, direct manufacturing costs and API manufacturing market, we have developed informed estimates on the financial evolution of the market, over the period 2020-2030. The report also provides details on the likely distribution of the current and forecasted opportunity across [A] reaction conditions (low temperature, high temperature, low pressure, high pressure), [B] company size (small, mid-sized, large / very large) and [C] region (North America, Europe and Asia Pacific) and [D] scale of operation (preclinical / clinical, commercial). In order to account for future uncertainties and to add robustness to our forecast model, we have provided three scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth. 

The opinions and insights presented in this study were also influenced by discussions conducted with stakeholders in this domain. All actual figures have been sourced and analyzed from publicly available information forums. Financial figures mentioned in this report are in USD, unless otherwise specified.

Contents

Chapter Outlines

Chapter 2 provides an executive summary of the key insights captured in our research. The summary offers a high-level view on the likely evolution of contract and custom API manufacturing market based on high energy chemistry, in the short-mid and long term.

Chapter 3 provides a general introduction to high energy chemistry. It also presents information on the different types of high energy reactions (such as high temperature reactions, low temperature / cryogenic reactions, high pressure reactions and hazardous reactions), along with details related to the advantages offered, affiliated production processes, other specific requirements or equipment required for such procedures. Additionally, it includes a discussion on the recent trends observed with this domain, including increasing demand for novel chemistry reactions and shift towards continuous flow technology.

Chapter 4 is a case study comparing the key characteristics of large and small molecule drugs, along with information on the steps involved in their respective manufacturing processes. In addition, it highlights the information on the key manufacturing challenges associated with small molecules and large molecules.

Chapter 5 provides detailed review of the overall landscape of companies offering contract and custom services for HEC / hazardous chemistry-based API manufacturing, along with information on type of manufacturer (contract and custom manufacturer), year of establishment, company size, location of headquarters, number and location of manufacturing facilities, general service portfolio (type of product (APIs, intermediates, and drug products), HPAPI manufacturing capability and availability of continuous flow technology), HEC specific service portfolio (type of  conditions handled such as high temperature, low temperature, high pressure, low pressure for API manufacturing processes). 

Chapter 6 includes a detailed list of over 125 manufacturing facilities equipped to handle API manufacturing processes / reactions under high temperature, low temperature, high pressure and low pressure conditions. The chapter features geographical map representations highlighting the location of these manufacturing facilities, along with logo landscape of manufacturers. The chapter also presents a detailed regional capability assessment framework which compares the capabilities of companies (based on manufacturing facilities) across different regions. It further include information on type of reaction conditions handled (high temperature, low temperature, high pressure, low pressure) and operating range.

Chapter 7 includes 3-D bubble competitiveness analysis of HEC / hazardous chemistry-based contract and custom manufacturers, taking into consideration supplier strength (based year of establishment), service strength (general service portfolio (API, intermediate and FDF, availability of continuous flow technology), HEC / hazardous chemistry-based service portfolio (capability to handle API manufacturing processes under conditions, including high temperature, low temperature, high pressure, low pressure and other hazardous reaction capabilities), and number of HEC-specific manufacturing facilities of companies.

Chapter 8 presents elaborate profiles of the key players that offer a diverse range of capabilities for API manufacturing based on HEC / hazardous chemistry. Each profile includes a brief overview of the company, financial information (if available), details related to manufacturing facilities (pharmaceutical manufacturing facilities and HEC / hazardous chemistry specific facilities), information related to its HEC / hazardous chemistry based API manufacturing service portfolio (high temperature and low temperature reaction conditions handled, portfolio of hazardous reactions), recent developments and an informed future outlook.

Chapter 9 features a case study providing insights on the general reaction portfolio related to small molecule synthesis processes. We have presented this information for HEC / hazardous chemistry-based companies, along with information on the availability of continuous flow technology and capabilities to handle varied reaction conditions, such as high temperature, low temperature, high pressure, and low pressure controls.

Chapter 10 includes a detailed case study presenting a list of contract research organizations (CROs) and custom synthesis service providers which claim to have the required capabilities to provide a wide range of services, ranging from process development (including preliminary R&D), scale-up and small scale synthesis, for APIs based on HEC / hazardous chemistry.

Chapter 11 features an elaborate market forecast analysis highlighting the likely growth of HEC/ hazardous chemistry-based API manufacturing services market, till the year 2030. In order to provide details on the future opportunity, our projections have been segmented on the basis of  [A] reaction conditions (low temperature, high temperature, low pressure, high pressure), [B] company size (small, mid-sized, large / very large) and [C] region (North America, Europe and Asia Pacific) and [D] scale of operation (preclinical / clinical, commercial). In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

Chapter 12 presents a discussion on affiliated trends, key drivers and challenges, under a comprehensive SWOT framework, which are likely to impact the industry’s evolution, including a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall industry.

Chapter 13 is a collection of transcripts of the interviews conducted with representatives from renowned organizations that are engaged in this domain.

Chapter 14 highlights the effect of coronavirus outbreak on the global pharmaceutical industry. It includes a brief discussion on the short-term and long-term impact of COVID-19 upsurge on the supply chain and market opportunity for drug developers and CMOs. In addition, it includes a brief section on strategies and action plans that pharma companies are likely to adopt in order to prepare for supply chain disruptions in future.

Chapter 15 is a summary of the overall report. It includes key takeaways related to research and analysis from the report in an infographic format.

Chapter 16 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Overview of High Energy Chemistry (HEC) / Hazardous Chemistry for Small Molecule API Manufacturing
3.3. Low Temperature / Cryogenic Chemistry
3.3.1. Reaction Conditions
3.3.2. Advantages
3.3.3. Affiliated Production Processes
3.3.4. Other Specific Requirements / Equipment

3.4. High Temperature Chemistry
3.4.1. Reaction Conditions
3.4.2. Advantages
3.4.3. Affiliated Production Processes
3.4.4. Other Specific Requirements / Equipment

3.5. High Pressure Chemistry
3.5.1. Reaction Conditions
3.5.2. Advantages
3.5.3. Affiliated Production Processes
3.5.4. Other Specific Requirements / Equipment

3.6. Low Pressure Chemistry
3.6.1. Reaction Conditions
3.6.2. Advantages
3.6.3. Affiliated Production Processes
3.6.4. Other Specific Requirements / Equipment

3.7. Need for HEC / Hazardous Chemistry for Small Molecule Manufacturing
3.7.1. Development of New and Complex Molecular Structures
3.7.2. Low Cost Generic API Synthesis
3.7.3. Route Scouting for Novel, Complex Molecules

3.8. Shift Towards Continuous Flow Chemistry

4. CASE STUDY: COMPARISON OF SMALL MOLECULES AND LARGE MOLECULES
4.1. Chapter Overview
4.2. Small Molecule and Large Molecule Drugs / Therapies 
4.2.1. Comparison of Key Characteristics
4.2.2. Comparison of Manufacturing Processes
4.2.3. Comparison of Key Manufacturing-related Challenges

5. CURRENT MARKET LANDSCAPE
5.1. Chapter Overview
5.2. API Manufacturers with HEC Capability: Overall Market Landscape

5.2.1. Analysis by Type of Manufacturing Service
5.2.2. Analysis by Year of Establishment
5.2.3. Analysis by Company Size
5.2.4. Analysis by Geographical Location
5.2.5. Analysis by Location of Manufacturing Facilities

5.2.6. Analysis by General Pharmaceutical Manufacturing Portfolio
5.2.6.1. Analysis by Type of Product (API and FDF)
5.2.6.2. Analysis by HPAPI Manufacturing Capability
5.2.7. Analysis by Type of HEC Services Offered
5.2.7.1. Analysis by Temperature Conditions Handled
5.2.7.2. Analysis by Pressure Conditions Handled
5.2.8. Analysis by Availability of Continuous Flow Technology

6. REGIONAL CAPABILITY ASSESSMENT
6.1. Chapter Overview
6.2. List of Manufacturing Facilities having HEC Capabilities

6.2.1. Manufacturing Facilities in North America
6.2.1.1. Geographical Map Representation: Manufacturing Facilities with HEC Capabilities in North America
6.2.1.2. Analysis by Type of Reaction Conditions Handled
6.2.1.3. Analysis by Range of Reaction Conditions Handled
6.2.1.3.1. Analysis by Temperature Conditions Handled
6.2.1.3.2. Analysis by Pressure Conditions Handled

6.2.2. Manufacturing Facilities in Europe
6.2.2.1. Geographical Map Representation: Manufacturing Facilities with HEC Capabilities in Europe
6.2.2.2. Analysis by Type of Reaction Conditions Handled
6.2.2.3. Analysis by Range of Reaction Conditions Handled
6.2.2.3.1. Analysis by Temperature Conditions Handled
6.2.2.3.2. Analysis by Pressure Conditions Handled

6.2.3. Manufacturing Facilities in Asia Pacific
6.2.3.1. Geographical Map Representation: Manufacturing Facilities with HEC Capabilities in Asia Pacific
6.2.3.2. Analysis by Type of Reaction Conditions Handled
6.2.3.3. Analysis by Range of Reaction Conditions Handled
6.2.3.3.1. Analysis by Temperature Conditions Handled
6.2.3.3.2. Analysis by Pressure Conditions Handled

6.3. Regional Capability Assessment Summary

7. COMPANY COMPETITIVENESS ANALYSIS
7.1. Chapter Overview
7.2. Key Parameters
7.3. Methodology

7.4. Competitiveness Analysis: Companies in North America
7.4.1. Companies in North America Offering HEC-based Contract Manufacturing
7.4.2. Companies in North America Offering HEC-based Custom Manufacturing

7.5. Competitiveness Analysis: Companies in Europe
7.5.1. Companies in Europe Offering HEC-based Contract Manufacturing
7.5.2. Companies in Europe Offering HEC-based Custom Manufacturing

7.6. Competitiveness Analysis: Companies in Asia Pacific
7.6.1. Companies in Asia Pacific Offering HEC-based Contract Manufacturing
7.6.2. Companies in Asia Pacific HEC-based Offering Custom Manufacturing

7.7. Spider Web Analysis

8. COMPANY PROFILES
8.1. Chapter Overview
8.2. AGC Chemicals
8.2.1. Company Overview
8.2.2. Financial Information
8.2.3. Manufacturing Facility Details
8.2.4. HEC Specific Service Offerings
8.2.5. Recent Developments and Future Outlook

8.3. Beijing Mediking Biopharm
8.3.1 Company Overview
8.3.2 Manufacturing Facility Details
8.3.3 HEC Specific Service Offerings
8.3.4. Recent Developments and Future Outlook

8.4. Cambrex
8.4.1. Company Overview
8.4.2. Financial Information
8.4.3. Manufacturing Facility Details
8.4.4. HEC Specific Service Offerings
8.4.5. Recent Developments and Future Outlook

8.5. Corden Pharma
8.5.1 Company Overview
8.5.2 Manufacturing Facility Details
8.5.3 HEC Specific Service Offerings
8.5.4 Recent Developments and Future Outlook

8.6. Evonik
8.6.1. Company Overview
8.6.2. Financial Information
8.6.3. Manufacturing Facility Details
8.6.4. HEC Specific Service Offerings
8.6.5. Recent Developments and Future Outlook

8.7. Hovione
8.7.1. Company Overview
8.7.2. Manufacturing Facility Details
8.7.3. HEC Specific Service Offerings
8.7.4. Recent Developments and Future Outlook

8.8. Patheon
8.8.1. Company Overview
8.8.2. Manufacturing Facility Details
8.8.3. HEC Specific Service Offerings
8.8.4. Recent Developments and Future Outlook

8.9. PCI Synthesis
8.9.1. Company Overview
8.9.2. Manufacturing Facility Details
8.9.3. HEC Specific Service Offerings
8.9.4. Recent Developments and Future Outlook

8.10. Siegfried
8.10.1. Company Overview
8.10.2. Manufacturing Facility Details
8.10.3. HEC Specific Service Offerings
8.10.4. Financial Information
8.10.5. Recent Developments and Future Outlook

9. CASE STUDY I: SYNTHESIS REACTION PORTFOLIO OF COMPANIES
9.1. Context and Background
9.2. Reaction Portfolios of API Manufacturers with HEC Capabilities

9.2.1. Analysis by Most Popular Reactions
9.2.1.1. Most Popular Reactions: Portfolio of Large Players
9.2.1.2. Most Popular Reactions: Portfolio of Mid-sized Players
9.2.1.3. Most Popular Reactions: Portfolio of Small Players
9.2.1.4. Most Popular Reactions: Portfolio of Other Players

9.2.2. Analysis by Moderately Popular Reactions
9.2.2.1. Moderately Popular Reactions: Portfolio of Large Players
9.2.2.2. Moderately Popular Reactions: Portfolio of Mid-sized Players
9.2.2.3. Moderately Popular Reactions: Portfolio of Small Players
9.2.2.4. Moderately Popular Reactions: Portfolio of Other Players

9.2.3. Analysis by Less Popular Reactions
9.2.3.1. Less Popular Reactions: Portfolio of Large Players
9.2.3.2. Less Popular Reactions: Portfolio of Mid-sized Players
9.2.3.3. Less Popular Reactions: Portfolio of Small Players
9.2.3.4. Less Popular Reactions: Portfolio of Other Players

9.2.4 Analysis by Least Popular Reactions

10. CASE STUDY II: INNOVATION MAPPING IN HEC MARKET
10.1. Context and Background
10.2. HEC-based Contract Research and Custom Synthesis Service Providers: Overall Market Landscape
10.2.1. Analysis by Year of Establishment
10.2.2. Analysis by Company Size
10.2.3. Analysis by Geographical Location
10.2.4. Analysis by HEC Conditions Handled
10.2.5. Analysis by Availability of Continuous Flow Technology
10.2.6. Company Competitiveness Analysis

11. MARKET FORECAST
11.1. Chapter Overview
11.2. Forecast Methodology and Key Assumptions
11.3. Global HEC-based API Manufacturing Services Market, 2020-2030

11.4. HEC-based API Manufacturing Services Market: Distribution by Region, 2020-2030
11.4.1. HEC-based API Manufacturing Services Market in North America
11.4.2. HEC-based API Manufacturing Services Market in Europe
11.4.3. HEC-based API Manufacturing Services Market in Asia Pacific

11.5. HEC-based API Manufacturing Services Market: Distribution by Reaction Conditions, 2020-2030
11.5.1. High Temperature Chemistry-based API Manufacturing Services Market, 2020-2030
11.5.1.1. High Temperature Chemistry-based API Manufacturing Services Market: Distribution by Region, 2020-2030
11.5.1.1.1. High Temperature Chemistry-based API Manufacturing Services Market in North America, 2020-2030
11.5.1.1.2. High Temperature Chemistry-based API Manufacturing Services Market in Europe, 2020-2030
11.5.1.1.3. High Temperature Chemistry-based API Manufacturing Services Market in Asia Pacific, 2020-2030

11.5.2. Low Temperature / Cryogenic Chemistry-based API Manufacturing Services Market, 2020-2030
11.5.2.1. Low Temperature / Cryogenic Chemistry-based API Manufacturing Services Market: Distribution by Region, 2020-2030
11.5.2.1.1. Low Temperature / Cryogenic Chemistry-based API Manufacturing Services Market in North America, 2020-2030
11.5.2.1.2. Low Temperature / Cryogenic Chemistry-based API Manufacturing Services Market in Europe, 2020-2030
11.5.2.1.3. Low Temperature / Cryogenic Chemistry-based API Manufacturing Services Market in Asia Pacific, 2020-2030

11.5.3. High Pressure Chemistry-based API Manufacturing Services Market, 2020-2030
11.5.3.1. High Pressure Chemistry-based API Manufacturing Services Market: Distribution by Region, 2020-2030
11.5.3.1.1. High Pressure Chemistry-based API Manufacturing Services Market in North America, 2020-2030
11.5.3.1.2. High Pressure Chemistry-based API Manufacturing Services Market in Europe, 2020-2030
11.5.3.1.3. High Pressure Chemistry-based API Manufacturing Services Market in Asia Pacific, 2020-2030

11.5.4. Low Pressure Chemistry-based API Manufacturing Services Market, 2020-2030
11.5.4.1. Low Pressure Chemistry-based API Manufacturing Services Market: Distribution by Region, 2020-2030
11.5.4.1.1. Low Pressure Chemistry-based API Manufacturing Services Market in North America, 2020-2030
11.5.4.1.2. Low Pressure Chemistry-based API Manufacturing Services Market in Europe, 2020-2030
11.5.4.1.3. Low Pressure Chemistry-based API Manufacturing Services Market in Asia Pacific, 2020-2030

11.6 HEC-Based API Manufacturing Services Market: Distribution by Scale of Operation, 2020-2030
11.6.1 Preclinical / Clinical Scale HEC-Based API Manufacturing Services Market, 2020-2030
11.6.2 Commercial Scale HEC-Based API Manufacturing Services Market, 2020-2030

11.7. Global HEC-Based API Manufacturing Services Market: Distribution by Company Size, 2020-2030
11.7.1. HEC-Based API Manufacturing Services Market: Share of Small Companies, 2020-2030
11.7.2. HEC-Based API Manufacturing Services Market: Share of Mid-sized Companies, 2020-2030
11.7.3. HEC-Based API Manufacturing Services Market: Share of Large / Very Large Companies, 2020-2030

12. SWOT ANALYSIS
12.1 Chapter Overview
12.2. SWOT Analysis
12.3. Strengths
12.4. Weaknesses
12.5. Opportunities
12.6. Threats
12.7. Concluding Remarks

13. EXECUTIVE INSIGHTS

14. COVID-19 IMPACT
14.1. Chapter Overview
14.2. Evaluation of Impact of COVID-19 Outbreak
14.2. Evaluation of Impact of COVID-19 Outbreak
14.2.1. Current Initiatives and Recuperative Initiatives of Key Players
14.2.2. Impact on the future opportunity for HEC / Hazardous Chemistry-based API Manufacturing Services Market
14.3. Recuperative Strategies: A Roots Analysis Perspective
14.3.1. Propositions for Immediate Implementation
14.3.2. Short / Long Term Steps

15. CONCLUSION

16. APPENDIX 1: TABULATED DATA

List Of Figures

Figure 3.1 Advantages of Continuous Flow Technology
Figure 4.1 Small Molecule and Large Molecule Drugs: Comparison of Key Characteristics
Figure 4.2 Small Molecule and Large Molecule Drugs: Comparison of Manufacturing Process
Figure 5.1 API Manufacturers with HEC Capability: Distribution by Type of Manufacturing Service
Figure 5.2 API Manufacturers with HEC Capability: Distribution by Year of Establishment
Figure 5.3 API Manufacturers with HEC Capability: Distribution by Company Size
Figure 5.4 API Manufacturers with HEC Capability: Distribution by Location of Headquarters (Region-wise)
Figure 5.5 API Manufacturers with HEC Capability: Distribution by Location of Headquarters (Country-wise)
Figure 5.6 API Manufacturers with HEC Capability: Distribution by General Pharmaceutical Manufacturing Portfolio (API and FDF)
Figure 5.7 API Manufacturers with HEC Capability: Distribution by HPAPI Manufacturing Capability
Figure 5.8 API Manufacturers with HEC Capability: Distribution by Type of HEC Conditions Handled
Figure 5.9 API Manufacturers with HEC Capability: Distribution by Availability of Continuous Flow Technology
Figure 6.1 Geographical Map Representation (North America): Distribution by Location and Number of Manufacturing Facilities with HEC Capabilities
Figure 6.2 Venn Diagram: Distribution of Manufacturing Facilities in North America by Type of Reaction Conditions Handled
Figure 6.3 Harvey Ball Analysis: Distribution of Manufacturing Facilities in North America by Operating Temperature Range
Figure 6.4 Harvey Ball Analysis: Distribution of Manufacturing Facilities in North America by Operating Pressure Range
Figure 6.5 Geographical Map Representation (Europe): Distribution by Location and Number of Manufacturing Facilities with HEC Capabilities
Figure 6.6 Venn Diagram: Distribution of Manufacturing Facilities in Europe by Type of Reaction Conditions Handled
Figure 6.7 Harvey Ball Analysis: Distribution of Manufacturing Facilities in Europe by Operating Temperature Range
Figure 6.8 Harvey Ball Analysis: Distribution of Manufacturing Facilities in Europe by Operating Pressure Range
Figure 6.9 Geographical Map Representation (Asia Pacific): Distribution by Location and Number of Manufacturing Facilities with HEC Capabilities
Figure 6.10 Venn Diagram: Distribution of Manufacturing Facilities in Asia Pacific by Type of Reaction Conditions Handled
Figure 6.11 Harvey Ball Analysis: Distribution of Manufacturing Facilities in Asia Pacific by Operating Temperature Range
Figure 6.12 Harvey Ball Analysis: Distribution of Manufacturing Facilities in Asia Pacific by Operating Pressure Range
Figure 6.13 Regional Capability Assessment
Figure 7.1 Company Competitiveness Analysis: HEC-based Contract Manufacturing Service Providers in North America
Figure 7.2 Company Competitiveness Analysis: HEC-based Custom Manufacturing Service Providers in North America
Figure 7.3 Company Competitiveness Analysis: HEC-based Contract Manufacturing Service Providers in Europe
Figure 7.4 Company Competitiveness Analysis: HEC-based Custom Service Providers in Europe
Figure 7.5 Company Competitiveness Analysis: HEC-based Contract Manufacturing Service Providers in Asia Pacific
Figure 7.6 Company Competitiveness Analysis: HEC-based Custom Manufacturing Service Providers in Asia Pacific
Figure 7.7 Spider Web Analysis: Benchmarking of Top Players
Figure 8.1 AGC: Annual Revenues, 2014 – Q1 2020 (USD Billion)
Figure 8.2 Cambrex: Annual Revenues, 2014 – Q3 2019 (USD Billion)
Figure 8.3 Evonik: Annual Revenues, 2014 – Q1 2020 (USD Billion)
Figure 8.4 Siegfried: Annual Revenues, 2014 – 2019 (USD Billion)
Figure 9.1 Reaction Portfolio of Companies: Distribution by Most Popular Reactions
Figure 9.2 List of Large Companies: Information on Reaction Portfolio (Most Popular Reactions), Conditions Handled and Availability of Continuous Flow Technology
Figure 9.3 List of Mid-sized Companies: Information on Reaction Portfolio (Most Popular Reactions), Conditions Handled and Availability of Continuous Flow Technology
Figure 9.4 List of Small Companies: Information on Reaction Portfolio (Most Popular Reactions), Conditions Handled and Availability of Continuous Flow Technology
Figure 9.5 List of Other Companies: Information on Reaction Portfolio (Most Popular Reactions), Conditions Handled and Availability of Continuous Flow Technology
Figure 9.6 Reaction Portfolio of Companies: Distribution by Moderately Popular Reactions
Figure 9.7 List of Large Companies: Information on Reaction Portfolio (Moderately Popular Reactions), Conditions Handled and Availability of Continuous Flow Technology
Figure 9.8 List of Mid-sized Companies: Information on Reaction Portfolio (Moderately Popular Reactions), Conditions Handled and Availability of Continuous Flow Technology
Figure 9.9 List of Small Companies: Information on Reaction Portfolio (Moderately Popular Reactions), Conditions Handled and Availability of Continuous Flow Technology
Figure 9.10 List of Other Companies: Information on Reaction Portfolio (Moderately Popular Reactions), Conditions Handled and Availability of Continuous Flow Technology
Figure 9.11 Reaction Portfolio of Companies: Distribution by Less Popular Reactions
Figure 9.12 List of Large Companies: Information on Reaction Portfolio (Less Popular Reactions), Conditions Handled and Availability of Continuous Flow Technology
Figure 9.13 List of Mid-sized Companies: Information on Reaction Portfolio (Less Popular Reactions), Conditions Handled and Availability of Continuous Flow Technology
Figure 9.14 List of Small Companies: Information on Reaction Portfolio (Less Popular Reactions), Conditions Handled and Availability of Continuous Flow Technology
Figure 9.15 List of Other Companies: Information on Reaction Portfolio (Less Popular Reactions), Conditions Handled and Availability of Continuous Flow Technology
Figure 9.16 Word Cloud of Least Popular Reactions
Figure 10.1 HEC-based Contract Research and Custom Synthesis Service Providers: Distribution by Year of Establishment
Figure 10.2 HEC-based Contract Research and Custom Synthesis Service Providers: Distribution by Company Size
Figure 10.3 HEC-based Contract Research and Custom Synthesis Service Providers: Distribution by Geographical Location
Figure 10.4 HEC-based Contract Research and Custom Synthesis Service Providers: Distribution by HEC Conditions Handled
Figure 10.5 HEC-based Contract Research and Custom Synthesis Service Providers: Distribution by Availability of Continuous Flow Technology
Figure 10.6 HEC-based Contract Research and Custom Synthesis Service Providers: Company Competitiveness
Figure 11.1 Overall HEC-based API Manufacturing Services Market, 2020-2030 (USD Billion)
Figure 11.2 HEC-based API Manufacturing Services Market: Distribution by Region, 2020-2030 (USD Billion)
Figure 11.3 HEC-based API Manufacturing Services Market in North America, 2020-2030 (USD Billion)
Figure 11.4 HEC-based API Manufacturing Services Market in Europe, 2020-2030 (USD Billion)
Figure 11.5 HEC-based API Manufacturing Services Market in Asia-Pacific, (USD Billion
Figure 11.6 HEC-based API Manufacturing Services Market: Distribution by Type of Reaction Conditions, 2020-2030 (USD Billion)
Figure 11.7 High Temperature Chemistry-based API Manufacturing Services Market, 2020-2030 (USD Billion)
Figure 11.8 High Temperature Chemistry-based API Manufacturing Services Market in North America, 2020-2030
Figure 11.9 High Temperature Chemistry-based API Manufacturing Services Market in Europe, 2020-2030
Figure 11.10 High Temperature Chemistry-based API Manufacturing Services Market in Asia Pacific, 2020-2030
Figure 11.11 Low Temperature Chemistry-based API Manufacturing Services Market, 2020-2030 (USD Billion)
Figure 11.12 Low Temperature / Cryogenic Chemistry-based API Manufacturing Services Market in North America, 2020-2030
Figure 11.13 Low Temperature / Cryogenic Chemistry-based API Manufacturing Services Market in Europe, 2020-2030
Figure 11.14 Low Temperature / Cryogenic Chemistry-based API Manufacturing Services Market in Asia Pacific, 2020-2030
Figure 11.15 High Pressure Chemistry-based API Manufacturing Services Market, 2020-2030 (USD Billion)
Figure 11.16 High Pressure Chemistry-based API Manufacturing Services Market in North America, 2020-2030 (USD Billion)
Figure 11.17 High Pressure Chemistry-based API Manufacturing Services Market in Europe, 2020-2030 (USD Billion)
Figure 11.18 High Pressure Chemistry-based API Manufacturing Services Market in Asia Pacific, 2020-2030 (USD Billion)
Figure 11.19 Low Pressure Chemistry-based API Manufacturing Services Market, 2020-2030 (USD Billion)
Figure 11.20 Low Pressure Chemistry-based API Manufacturing Services Market in North America, 2020-2030 (USD Billion)
Figure 11.21 Low Pressure Chemistry-based API Manufacturing Services Market in Europe, 2020-2030 (USD Billion)
Figure 11.22 Low Pressure Chemistry-based API Manufacturing Services Market in Asia Pacific, 2020-2030 (USD Billion)
Figure 11.23 HEC-based API Manufacturing Services Market: Distribution by Scale of Operation, 2020-2030 (USD Billion)
Figure 11.24 Preclinical / Clinical Scale HEC-based API Manufacturing Services Market, 2020-2030 (USD Billion)
Figure 11.25 Commercial Scale HEC-based API Manufacturing Services Market, 2020-2030 (USD Billion)
Figure 11.26 HEC-Based API Manufacturing Services Market: Distribution by Company Size, 2020-2030 (USD Billion)
Figure 11.27 HEC-Based API Manufacturing Services Market: Share of Small Companies, 2020-2030 (USD Billion)
Figure 11.28 HEC-Based API Manufacturing Services Market: Share of Mid-sized Companies, 2020-2030 (USD Billion)
Figure 11.29 HEC-Based API Manufacturing Services Market: Share of Large / Very Large Companies, 2020-2030 (USD Billion)
Figure 12.1 HEC-based API Manufacturing Services Market: SWOT Factors
Figure 12.2 Comparison of SWOT Factors: Harvey Ball Analysis

List Of Tables

Table 3.1 List of Low Temperature / Cryogenic Reactions
Table 3.2 List of High Temperature Reactions
Table 3.3 List of High Pressure Reactions
Table 3.4 List of HEC / Hazardous Reactions
Table 4.1 Small Molecules and Large Molecules: Comparison of Development Characteristics
Table 5.1 List of API Manufacturers with HEC Capability: Information on Type of Manufacturing Service, Year of Establishment, Company Size, Location of Headquarters
Table 5.2 List of API Manufacturers with HEC Capability: Information on Number and Location of Global Pharmaceutical Manufacturing Facilities and API Manufacturing Facilities with HEC Capability
Table 5.3 List of API Manufacturers with HEC Capability: Information on General Pharmaceutical Manufacturing Portfolio
Table 5.4 List of API Manufacturers with HEC Capability: Information on HEC Conditions Handled
Table 5.5 List of API Manufacturers with HEC Capability: Information on Reaction Operating Range
Table 5.6 API Manufacturers with HEC Capability: Information on Temperature Conditions Handled
Table 5.7 API Manufacturers with HEC Capability: Information on Pressure Conditions Handled
Table 6.1 List of API Manufacturing Facilities with HEC Capability: Information on Number and Location
Table 6.2 List of API Manufacturing Facilities with HEC Capability: Information on Type HEC Conditions Handled
Table 6.3 List of API Manufacturing Facilities in North America with HEC Capability: Information on Reaction Conditions Handled
Table 6.4 List of API Manufacturing Facilities in Europe with HEC Capability: Information on Reaction Conditions Handled
Table 6.5 List of API Manufacturing Facilities in Asia Pacific with HEC Capability: Information on Reaction Conditions Handled
Table 8.1 AGC Chemicals: Company Overview
Table 8.2 AGC Chemicals: Manufacturing Facility Details
Table 8.3 AGC Chemicals: HEC / Hazardous Chemistry Specific Service Offerings
Table 8.4 Beijing Mediking Biopharm: Company Overview
Table 8.5 Beijing Mediking Biopharm: Manufacturing Facility Details
Table 8.6 Beijing Mediking Biopharm: HEC / Hazardous Chemistry Specific Service Offerings
Table 8.7 Cambrex: Company Overview
Table 8.8 Cambrex: Manufacturing Facility Details
Table 8.9 Cambrex: HEC / Hazardous Chemistry Specific Service Offerings
Table 8.10 Cambrex: Recent Developments and Future Outlook
Table 8.11 Corden Pharma: Company Overview
Table 8.12 Corden Pharma: Manufacturing Facility Details
Table 8.13 Corden Pharma: HEC / Hazardous Chemistry Specific Service Offerings
Table 8.14 Corden Pharma: Recent Developments and Future Outlook
Table 8.15 Evonik: Company Overview
Table 8.16 Evonik: Manufacturing Facility Details
Table 8.17 Evonik: HEC / Hazardous Chemistry Specific Service Offerings
Table 8.18 Hovione: Company Overview
Table 8.19 Hovione: Manufacturing Facility Details
Table 8.20 Hovione: HEC / Hazardous Chemistry Specific Service Offerings
Table 8.21 Hovione: Recent Developments and Future Outlook
Table 8.22 Patheon: Company Overview
Table 8.23 Patheon: Manufacturing Facility Details
Table 8.24 Patheon: HEC / Hazardous Chemistry Specific Service Offerings
Table 8.25 PCI Synthesis: Company Overview
Table 8.26 PCI Synthesis: Manufacturing Facility Details
Table 8.27 PCI Synthesis: HEC / Hazardous Chemistry Specific Service Offerings
Table 8.28 PCI Synthesis: Recent Developments and Future Outlook
Table 8.29 Siegfried: Company Overview
Table 8.30 Siegfried: Manufacturing Facility Details
Table 8.31 Siegfried: HEC / Hazardous Chemistry Specific Service Offerings
Table 8.32 Siegfried: Recent Developments and Future Outlook
Table 10.1 List of HEC-based Contract Research and Custom Synthesis Service Providers: Information on Year of Establishment, Company Size, Location of Headquarters, HEC Conditions Handled
Table 16.1 API Manufacturers with HEC Capability: Distribution by Type of Manufacturing Service
Table 16.2 API Manufacturers with HEC Capability: Distribution by Year of Establishment
Table 16.3 API Manufacturers with HEC Capability: Distribution by Company Size
Table 16.4 API Manufacturers with HEC Capability: Distribution by Location of Headquarters
Table 16.5 List of API Manufacturers with HEC Capability: Information on General Pharmaceutical Manufacturing Portfolio
Table 16.6 API Manufacturers with HEC Capability: Distribution by General Pharmaceutical Manufacturing Portfolio (API and FDF)
Table 16.7 API Manufacturers with HEC Capability: Distribution by HPAPAI Manufacturing Capability
Table 16.8 API Manufacturers with HEC Capability: Distribution by Type of HEC Conditions Handled
Table 16.9 API Manufacturers with HEC Capability: Distribution by Type of High Temperature Condition Handled
Table 16.10 API Manufacturers with HEC Capability: Distribution by Type of Low Temperature Condition Handled
Table 16.11 API Manufacturers with HEC Capability: Distribution by Type of High Pressure Condition Handled
Table 16.12 API Manufacturers with HEC Capability: Distribution by Type of Low Pressure Condition Handled
Table 16.13 List of API Manufacturing Facilities with HEC Capability: Information on Number and Location
Table 16.14 List of API Manufacturing Facilities with HEC Capability: Information on Type HEC Conditions Handled
Table 16.15 Venn Diagram: Distribution of Manufacturing Facilities in North America by Type of Reaction Conditions Handled
Table 16.16 Venn Diagram: Distribution of Manufacturing Facilities in Europe by Type of Reaction Conditions Handled
Table 16.17 Venn Diagram: Distribution of Manufacturing Facilities in Asia Pacific by Type of Reaction Conditions Handled
Table 16.18 AGC Chemicals: Annual Revenues, 2014 – 2019 (USD Billion)
Table 16.19 Cambrex: Annual Revenues, 2014 – 2019 (USD Billion)
Table 16.20 Evonik: Annual Revenues, 2014 – 2019 (USD Billion)
Table 16.21 Siegfried: Annual Revenues, 2014 – 2019 (USD Billion)
Table 16.22 Reaction Portfolio of Companies: Distribution by Most Popular Reactions
Table 16.23 Reaction Portfolio of Companies: Distribution by Less Popular Reactions
Table 16.24 Reaction Portfolio of Companies: Distribution by Most Popular Reactions
Table 16.25 HEC-based Contract Research and Custom Synthesis Service Providers: Distribution by Year of Establishment
Table 16.26 HEC-based Contract Research and Custom Synthesis Service Providers: Distribution by Company Size
Table 16.27 HEC-based Contract Research and Custom Synthesis Service Providers: Distribution by Geographical Location
Table 16.28 HEC-based Contract Research and Custom Synthesis Service Providers: Distribution by HEC Conditions Handled and Geographical Location
Table 16.29 HEC-based Contract Research and Custom Synthesis Service Providers: Distribution by Availability of Continuous Flow Technology
Table 16.30 Overall HEC-based API Manufacturing Services Market, 2020-2030 (USD Billion)
Table 16.31 HEC-based API Manufacturing Services Market: Distribution by Region, 2020-2030 (USD Billion)
Table 16.32 HEC-based API Manufacturing Services Market in North America, 2020-2030 (USD Billion)
Table 16.33 HEC-based API Manufacturing Services Market in Europe, 2020-2030 (USD Billion)
Table 16.34 HEC-based API Manufacturing Services Market in Asia-Pacific, (USD Billion
Table 16.35 HEC-based API Manufacturing Services Market: Distribution by Type of Reaction Conditions, 2020-2030 (USD Billion)
Table 16.36 High Temperature Chemistry-based API Manufacturing Services Market, 2020-2030 (USD Billion)
Table 16.37 High Temperature Chemistry-based API Manufacturing Services Market in North America, 2020-2030
Table 16.38 High Temperature Chemistry-based API Manufacturing Services Market in Europe, 2020-2030
Table 16.39 High Temperature Chemistry-based API Manufacturing Services Market in Asia Pacific, 2020-2030
Table 16.40 Low Temperature Chemistry-based API Manufacturing Services Market, 2020-2030 (USD Billion)
Table 16.41 Low Temperature / Cryogenic Chemistry-based API Manufacturing Services Market in North America, 2020-2030
Table 16.42 Low Temperature / Cryogenic Chemistry-based API Manufacturing Services Market in Europe, 2020-2030
Table 16.43 Low Temperature / Cryogenic Chemistry-based API Manufacturing Services Market in Asia Pacific, 2020-2030
Table 16.44 High Pressure Chemistry-based API Manufacturing Services Market, 2020-2030 (USD Billion)
Table 16.45 High Pressure Chemistry-based API Manufacturing Services Market in North America, 2020-2030 (USD Billion)
Table 16.46 High Pressure Chemistry-based API Manufacturing Services Market in Europe, 2020-2030 (USD Billion)
Table 16.47 High Pressure Chemistry-based API Manufacturing Services Market in Asia Pacific, 2020-2030 (USD Billion)
Table 16.48 Low Pressure Chemistry-based API Manufacturing Services Market, 2020-2030 (USD Billion)
Table 16.49 Low Pressure Chemistry-based API Manufacturing Services Market in North America, 2020-2030 (USD Billion)
Table 16.50 Low Pressure Chemistry-based API Manufacturing Services Market in Europe, 2020-2030 (USD Billion)
Table 16.51 Low Pressure Chemistry-based API Manufacturing Services Market in Asia Pacific, 2020-2030 (USD Billion)
Table 16.52 HEC-based API Manufacturing Services Market: Distribution by Scale of Operation, 2020-2030 (USD Billion)
Table 16.53 Preclinical / Clinical Scale HEC-based API Manufacturing Services Market, 2020-2030 (USD Billion)
Table 16.54 Commercial Scale HEC-based API Manufacturing Services Market, 2020-2030 (USD Billion)
Table 16.55 HEC-Based API Manufacturing Services Market: Distribution by Company Size, 2020-2030 (USD Billion)
Table 16.56 HEC-Based API Manufacturing Services Market: Share of Small Companies, 2020-2030 (USD Billion)
Table 16.57 HEC-Based API Manufacturing Services Market: Share of Mid-sized Companies, 2020-2030 (USD Billion)
Table 16.58 HEC-Based API Manufacturing Services Market: Share of Large / Very Large Companies, 2020-2030 (USD Billion)

Listed Companies

The following companies and organizations have been mentioned in the report.

  1. 3A Chemie
  2. Aarti Drugs
  3. ABA Chemicals
  4. Acharya Group
  5. Aether
  6. AGC Chemicals
  7. Ajinomoto Bio-Pharma
  8. Albemarle
  9. Alcami 
  10. Almac 
  11. Alven Laboratories
  12. Amar Chemistry
  13. AMPAC Fine Chemicals
  14. AMRI
  15. AnaCipher
  16. Analytica Chemie
  17. Angelini Pharma
  18. Anthem Biosciences
  19. Anuh Pharma
  20. Anvi Pharmaceuticals 
  21. Apeloa Pharmaceutical
  22. Apex Molecular
  23. APIchem 
  24. APICMO
  25. Arch Pharmalabs
  26. Arevipharma
  27. ASolution Pharmaceuticals
  28. Asymchem
  29. Austin Chemical 
  30. Avara Pharmaceutical 
  31. Avigna Pharma
  32. Avista Pharma Solutions
  33. Avra Laboratories
  34. Bachem
  35. BASF
  36. Beijing Mediking Biopharm
  37. Biddle Sawyer
  38. Bioindustria L.I.M
  39. Cambrex 
  40. Chandra Life Sciences
  41. Changzhou Carbochem
  42. ChemCon
  43. ChemFuture PharmaTech
  44. Chemigran
  45. Chemsigma International
  46. Chemwill Asia 
  47. ChengDu TongChuangYuan Pharmaceutical
  48. Chiral Biosciences
  49. Chromo Laboratories
  50. CiVentiChem
  51. Corden Pharma
  52. CsFlowChem
  53. Dalton Pharma Services
  54. Delmar
  55. Dipharma
  56. Dishman 
  57. DIVERCHIM
  58. Divi's Laboratories
  59. DOTTIKON ES
  60. Dr. Reddy’s Laboratories 
  61. DSL Chemicals
  62. Enaltec 
  63. Enbridge PharmTech
  64. Esteve Química
  65. Eurofins Alphora
  66. Evonik
  67. Evotec
  68. Fareva
  69. Farmak
  70. Farmhispania 
  71. FDC 
  72. F.I.S. – Fabbrica Italiana Sintetici 
  73. Flamma
  74. Fuji Chemical Industries
  75. Fujimoto Chemicals 
  76. Grace
  77. GVK Biosciences
  78. Hangzhou Chemipanda Bio-Tech
  79. Hangzhou Panyu Chemical 
  80. Helsinn Healthcare
  81. Hikal 
  82. Hisun Pharmaceuticals USA
  83. Holochem
  84. Hovione
  85. Hubei Biocause Pharmaceutical
  86. ICROM
  87. Ind-Swift Laboratories
  88. Inventys
  89. IPOCHEM
  90. Iwaki Seiyaku 
  91. Jiangsu Allyrise Pharmaceutical 
  92. Jiangsu Quality Horizons Pharmtech
  93. Jiangxi Long Life Bio-pharmaceutical
  94. Johnson Matthey
  95. K.A.Malle Pharmaceuticals
  96. Keryx Biopharmaceuticals
  97. Key Organics
  98. Kingchem Life Science
  99. Kongo Chemical
  100. Kopran
  101. KriSan Biotech 
  102. Lebsa 
  103. LOBA Feinchemie
  104. Lonza
  105. M2i Life Sciences
  106. Maithili Life Sciences
  107. Malladi 
  108. Mankind Pharma
  109. Medichem
  110. Medkem
  111. MENADIONA
  112. MercachemSyncom
  113. Metrochem API
  114. MINAKEM
  115. Modepro India
  116. Morepen
  117. MSN Laboratories 
  118. Nanjing Finetech Chemical
  119. Nanjing Pharmatechs
  120. NCK
  121. NerPharMa
  122. Neuland Laboratories
  123. Norchim
  124. Novasep
  125. Olon
  126. Oman Chemicals & Pharmaceuticals
  127. Onyx Scientific
  128. Orchid Chemicals & Pharamaceuticals
  129. Patheon
  130. PCI Synthesis
  131. Pfanstiehl 
  132. Pfizer
  133. Pfizer CentreOne
  134. PharmaCore
  135. Pharmaron
  136. PharmaZell
  137. Pi-Process Intensification
  138. Pi-Process Intensification
  139. Piramal Pharma Solutions 
  140. PMC Isochem
  141. Porton Pharma Solutions 
  142. Procos 
  143. Quality Horizons
  144. RA Chem Pharma 
  145. Rakshit Drugs
  146. Raybow Pharma
  147. Recipharm
  148. Recordati 
  149. Regis Technologies
  150. Richman Chemical
  151. Robinson Brothers
  152. Sai Life Sciences 
  153. Sambi Pharma
  154. Saniver 
  155. Saurav Chemicals
  156. SCI Pharmtech
  157. ScinoPharm Taiwan 
  158. Seqens
  159. SeQuent
  160. Servier
  161. Shanghai Hobor Chemical
  162. Shanghai Ruiyi Medical Tech
  163. Sharon Bio-Medicine
  164. Siegfried 
  165. Sinolite 
  166. SK biotek
  167. Snapdragon Chemistry
  168. Solara Active Pharma Sciences 
  169. Solvias
  170. SONEAS
  171. Spectrum Chemical Manufacturing 
  172. SRC Laboratories
  173. Sterling Pharma Solutions
  174. Sumitomo Chemical
  175. Synthelia 
  176. THINQ Pharma
  177. Tianjin Pharmacn Medical Technology 
  178. UBE Industries
  179. Valsynthese
  180. Vamsi Labs 
  181. Vinkem
  182. WeylChem InnoTec
  183. Wisdom Pharmaceutical
  184. WuXi STA
  185. XINXIANG BEST PHARMACEUTICAL 
  186. Zambon
  187. ZCL Chemicals
  188. Zhejiang Changming Pharmaceutical
  189. ZHIWE ChemTech 

Request Customization

Please select a suitable option for customization in the report

PRICING DETAILS

USD 4,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site / office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm / enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com